Blog
RSS FeedPosted by Michael Wonder on 27 Apr 2022
Venetoclax with low dose cytarabine for untreated acute myeloid leukaemia
27 April 2022 - NICE has published evidence-based recommendations on the use of venetoclax in combination with low dose cytosine ...
Posted by Michael Wonder on 20 Apr 2022
NICE terminates appraisal of nivolumab
20 April 2022 - This is the first appraisal of nivolumab to be terminated by NICE. ...
Posted by Michael Wonder on 14 Apr 2022
Over 700 people a year could benefit from a new potentially life-extending lung cancer drug which targets a specific genetic mutation
14 April 2022 - An innovative and potentially life-extending drug for treating people with a specific gene mutation of advanced ...
Posted by Michael Wonder on 13 Apr 2022
NICE backs Biogen’s Vumerity for multiple sclerosis
13 April 2022 - Patients with relapsing-remitting multiple sclerosis in England, Wales and Northern Ireland can now access treatment with ...
Posted by Michael Wonder on 09 Apr 2022
Upadacitinib, abrocitinib and tralokinumab for atopic dermatitis
8 April 2022 - A rare multiple technology assessment from NICE. ...
Posted by Michael Wonder on 08 Apr 2022
NICE recommends Koselugo for the treatment of neurofibromatosis type 1
8 April 2022 - NICE has recommended AstraZeneca and MSD’s Koselugo (selumetinib) for use by the NHS in England, within ...
Posted by Michael Wonder on 07 Apr 2022
NICE says new triple negative advanced breast cancer drug too expensive for NHS use
7 April 2022 - NICE has today issued draft guidance which does not recommend sacituzumab govitecan for treating locally advanced or ...
Posted by Michael Wonder on 07 Apr 2022
Hundreds of people with some forms of urothelial cancer to receive new treatment
7 April 2022 - Over 800 people with locally advanced or metastatic urothelial cancer are set to benefit from a new ...
Posted by Michael Wonder on 01 Apr 2022
Thousands of people set to benefit from first new treatment for osteoporosis for over a decade
1 April 2022 - Thousands of people in England and Wales with severe osteoporosis who are at high risk of fracture ...
Posted by Michael Wonder on 30 Mar 2022
Tagraxofusp for treating blastic plasmacytoid dendritic cell neoplasm
30 March 2022 - Tagraxofusp is human interleukin-3 genetically conjugated to diphtheria toxin protein. ...
Posted by Michael Wonder on 28 Mar 2022
Atidarsagene autotemcel for treating metachromatic leukodystrophy
28 March 2022 - NICE has published evidence-based recommendations on atidarsagene autotemcel (Libmeldy) for treating metachromatic leukodystrophy in children. ...
Posted by Michael Wonder on 24 Mar 2022
Nivolumab with ipilimumab for untreated advanced renal cell carcinoma
24 March 2022 - NICE has published evidence-based recommendations on nivolumab (Opdivo) with ipilimumab (Yervoy) for untreated advanced renal cell ...
Posted by Michael Wonder on 21 Mar 2022
NICE recommends elosulfase alfa for routine NHS use for patients with rare life-limiting metabolic disorder
21 March 2022 - NICE has today published final draft guidance recommending elosulfase alfa (Vimizim; BioMarin) for routine use in ...
Posted by Michael Wonder on 16 Mar 2022
Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency
16 March 2022 - NICE has published evidence-based recommendations on the use of dostarlimab (Jemperli) for the treatment of adults ...
Posted by Michael Wonder on 10 Mar 2022
Solriamfetol for treating excessive daytime sleepiness caused by obstructive sleep apnoea
9 March 2022 - NICE has published evidence based recommendations on the use of solriamfetol hydrochloride (Sunosi) for the treatment ...